Maxonis
Maxonis has developed AGRG-based technology that effectively promotes nerve regeneration in patients with spinal cord injuries and peripheral nerve injuries, addressing the critical need for effective treatments in these areas. This patented solution has shown significant improvements in nerve repair outcomes during pre-clinical trials, offering a safer and simpler surgical procedure for patients with large nerve gaps.
- Biotechnology
Funding
Raised to date
$0Raised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 2 rounds
- Seed $0
- Accelerator $0
Founders
Product
Problem
Spinal cord injuries and peripheral nerve injuries often result in nerve damage that is difficult to repair, leading to limited treatment options and a reduced quality of life for affected individuals. Current treatments for large nerve gaps can be complex and carry significant surgical risks, while effective solutions for spinal cord injury repair remain elusive.
Solution
Maxonis is developing an AGRG-based technology designed to promote nerve regeneration in patients with spinal cord injuries (SCI) and peripheral nerve injuries (PNI). Their approach aims to address the unmet need for effective and safe nerve repair solutions, particularly for patients with large nerve gaps. Pre-clinical trials suggest that the AGRG-based treatment can significantly improve axonal growth in SCI and enhance nerve repair outcomes in PNI, offering a simpler surgical procedure with minimized risks.
Target Audience
The primary target audience includes patients with spinal cord injuries and peripheral nerve injuries, as well as surgeons and medical professionals specializing in nerve repair and regeneration.
Features
- AGRG-based technology to promote nerve regeneration.
- Treatment designed for both spinal cord injuries (SCI) and peripheral nerve injuries (PNI).
- Addresses the challenge of repairing large nerve gaps.
- Aims to offer a simpler surgical procedure compared to existing methods.
- Pre-clinical trials have demonstrated significant improvements in nerve regeneration and axonal growth.